Sandoz launches generic version of Vivelle-Dot

PRINCETON, N.J. — Sandoz has announced the U.S. market introduction of estradiol transdermal system, an authorized generic version of Vivelle-Dot, which is marketed by Novartis Pharmaceuticals.



Estradiol transdermal system is indicated for treatment of certain menopausal symptoms and for the prevention of postmenopausal osteoporosis.



“We are pleased to partner with our colleagues at NPC to further expand our offering of affordable, high-quality medicines,” said Peter Goldschmidt, president of Sandoz.



Sandoz will market the product in .025 mg/day, .0375 mg/day, .05 mg/day, .075 mg/day and .1 mg/day of estradiol, the same strengths marketed by Novartis Pharmaceuticals.

According to IMS Health, U.S. sales for estradiol transdermal system were $263 million for the 12 months ended September 2014.